Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AMLX logo AMLX
Upturn stock ratingUpturn stock rating
AMLX logo

Amylyx Pharmaceuticals Inc (AMLX)

Upturn stock ratingUpturn stock rating
$9.42
Last Close (24-hour delay)
Profit since last BUY46.96%
upturn advisory
Strong Buy
BUY since 47 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: AMLX (4-star) is a STRONG-BUY. BUY since 47 days. Profits (46.96%). Updated daily EoD!

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $12.62

1 Year Target Price $12.62

Analysts Price Target For last 52 week
$12.62 Target price
52w Low $2.08
Current$9.42
52w High $9.72

Analysis of Past Performance

Type Stock
Historic Profit -11.42%
Avg. Invested days 55
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 839.96M USD
Price to earnings Ratio -
1Y Target Price 12.62
Price to earnings Ratio -
1Y Target Price 12.62
Volume (30-day avg) 7
Beta -0.45
52 Weeks Range 2.08 - 9.72
Updated Date 08/29/2025
52 Weeks Range 2.08 - 9.72
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.49

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.46
Actual -0.46

Profitability

Profit Margin -
Operating Margin (TTM) 79106.43%

Management Effectiveness

Return on Assets (TTM) -46.74%
Return on Equity (TTM) -87.42%

Valuation

Trailing PE -
Forward PE 2.77
Enterprise Value 665093209
Price to Sales(TTM) 4.44
Enterprise Value 665093209
Price to Sales(TTM) 4.44
Enterprise Value to Revenue 6446.63
Enterprise Value to EBITDA -11.71
Shares Outstanding 89167400
Shares Floating 47960487
Shares Outstanding 89167400
Shares Floating 47960487
Percent Insiders 9.5
Percent Institutions 94.65

ai summary icon Upturn AI SWOT

Amylyx Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Amylyx Pharmaceuticals, Inc. was founded in 2013 by Justin Klee and Joshua Cohen. It focuses on developing treatments for neurodegenerative diseases. The company's early focus was on identifying novel therapies for ALS. A key milestone was the approval of Relyvrio for ALS in the US.

business area logo Core Business Areas

  • Neurodegenerative Disease Therapeutics: Develops and commercializes therapies for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS).

leadership logo Leadership and Structure

Joshua Cohen and Justin Klee serve as co-CEOs. The company has a board of directors and a management team overseeing research, development, commercialization, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • Relyvrio (sodium phenylbutyrate and taurursodiol): Relyvrio is a combination drug approved for the treatment of ALS. While precise market share data is difficult to ascertain due to limited treatment options, Relyvrio aims to address the disease's unmet need. Competitors include generic riluzole and edaravone (Radicava), both approved therapies for ALS.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry focusing on neurodegenerative diseases is characterized by high unmet needs and significant R&D investment. ALS, in particular, has limited treatment options.

Positioning

Amylyx is positioned as a company specializing in ALS therapeutics with an FDA-approved product. Its competitive advantage lies in Relyvrio, one of the few approved treatments for the disease.

Total Addressable Market (TAM)

The TAM for ALS therapeutics is estimated to be in the billions of dollars, given the high cost of treatment and the prevalence of the disease. Amylyx is positioned to capture a significant portion of this TAM with Relyvrio.

Upturn SWOT Analysis

Strengths

  • FDA-approved product (Relyvrio)
  • Focused on a high-need area (ALS)
  • Experienced leadership team

Weaknesses

  • Limited product pipeline
  • Reliance on a single product for revenue
  • Relatively small company size

Opportunities

  • Expansion of Relyvrio to other markets (e.g., Europe)
  • Development of new therapies for ALS and other neurodegenerative diseases
  • Partnerships and acquisitions

Threats

  • Competition from other ALS therapies
  • Regulatory hurdles
  • Clinical trial failures
  • Pricing and reimbursement pressures

Competitors and Market Share

competitor logo Key Competitors

  • ITCI
  • MTNB
  • IONS

Competitive Landscape

Amylyx has a competitive advantage with Relyvrio's approval, but faces competition from established pharmaceutical companies. The company's success depends on its ability to effectively commercialize Relyvrio and develop new therapies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is linked to the development and approval of Relyvrio, but quantitative data requires access to specific financial reports.

Future Projections: Future projections depend on Relyvrio sales, market expansion, and pipeline development. Analyst estimates change frequently.

Recent Initiatives: Recent initiatives include expanding access to Relyvrio, conducting post-marketing studies, and advancing pipeline programs.

Summary

Amylyx is a pharmaceutical company with an approved therapy, Relyvrio, for ALS, positioning it well in a high-need market. Its reliance on a single product makes it vulnerable, and successful commercialization of Relyvrio and pipeline expansion are crucial for long-term growth. Competition in the neurodegenerative disease space presents an ongoing threat. Amylyx needs to look to additional drug development to improve its financial outlook.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company press releases
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual risk tolerance and due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Amylyx Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2022-01-07
Co-Founder, Co-CEO & Director Mr. Joshua B. Cohen
Sector Healthcare
Industry Biotechnology
Full time employees 123
Full time employees 123

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.